Sestrin2 protein is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, which leads to the activation of the mTOR signaling pathway, suggesting that OTUD5 is activated by regulating the OTUD5/RNF186/sestrin2/mTOR axis to promote bladder cancer progression [78]. This evidence concerns the gene RNF186 and urinary bladder cancer.